CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM089444
035-os BibID:(cikkazonosító)190 (WOS)000595728400003 (Scopus)85096570971
Első szerző:Mahdi, Mohamed (orvos, tudományos segédmunkatárs)
Cím:Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2·s main protease / Mahdi Mohamed, Mótyán János András, Szojka Zsófia Ilona, Golda Mária, Miczi Márió, Tőzsér József
Dátum:2020
ISSN:1743-422X
Megjegyzések:Background: The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in millions of infections worldwide. While the search for an effective antiviral is still ongoing, experimental therapies based on repurposing of available antivirals is being attempted, of which HIV protease inhibitors (PIs) have gained considerable interest. Inhibition profiling of the PIs directly against the viral protease has never been attempted in vitro, and while few studies reported an efficacy of lopinavir and ritonavir in SARS-CoV-2 context, the mechanism of action of the drugs remains to be validated. Methods We carried out an in-depth analysis of the efficacy of HIV PIs against the main protease of SARS-CoV-2 (Mpro) in cell culture and in vitro enzymatic assays, using a methodology that enabled us to focus solely on any potential inhibitory effects of the inhibitors against the viral protease. For cell culture experiments a dark-to-bright GFP reporter substrate system was designed. Results Lopinavir, ritonavir, darunavir, saquinavir, and atazanavir were able to inhibit the viral protease in cell culture, albeit in concentrations much higher than their achievable plasma levels, given their current drug formulations. While inhibition by lopinavir was attributed to its cytotoxicity, ritonavir was the most effective of the panel, with IC50 of 13.7 ?M. None of the inhibitors showed significant inhibition of SARS-CoV-2 Mpro in our in vitro enzymatic assays up to 100 ?M concentration. Conclusion Targeting of SARS-CoV-2 Mpro by some of the HIV PIs might be of limited clinical potential, given the high concentration of the drugs required to achieve significant inhibition. Therefore, given their weak inhibition of the viral protease, any potential beneficial effect of the PIs in COVID-19 context might perhaps be attributed to acting on other molecular target(s), rather than SARS-CoV-2 Mpro.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
SARS-CoV-2
Inhibition profling
In vitro assay
HIV protease inhibitors
Protease
Megjelenés:Virology Journal. - 17 : 1 (2020), p. 1-8. -
További szerzők:Mótyán János András (1981-) (biokémikus, molekuláris biológus) Szojka Zsófia (1991-) (molekuláris biológus) Golda Mária (1986-) (molekuláris biológus) Miczi Márió Tőzsér József (1959-) (molekuláris biológus, biokémikus, vegyész)
Pályázati támogatás:NKFIH-1150?6/2019
Egyéb
NKFI 125238
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM089970
035-os BibID:(cikkazonosító)9523 (wos)000602881500001 (scopus)85098234996
Első szerző:Miczi Márió
Cím:Identification of Host Cellular Protein Substrates of SARS-COV-2 Main Protease / Márió Miczi, Mária Golda, Balázs Kunkli, Tibor Nagy, József Tőzsér, János András Mótyán
Dátum:2020
ISSN:1661-6596 1422-0067
Megjegyzések:The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease-19 (COVID-19) being associated with severe pneumonia. Like with other viruses, the interaction of SARS-CoV-2 with host cell proteins is necessary for successful replication, and cleavage of cellular targets by the viral protease also may contribute to the pathogenesis, but knowledge about the human proteins that are processed by the main protease (3CLpro) of SARS-CoV-2 is still limited. We tested the prediction potentials of two different in silico methods for the identification of SARS-CoV-2 3CLpro cleavage sites in human proteins. Short stretches of homologous host-pathogen protein sequences (SSHHPS) that are present in SARS-CoV-2 polyprotein and human proteins were identified using BLAST analysis, and the NetCorona 1.0 webserver was used to successfully predict cleavage sites, although this method was primarily developed for SARS-CoV. Human C-terminal-binding protein 1 (CTBP1) was found to be cleaved in vitro by SARS-CoV-2 3CLpro, the existence of the cleavage site was proved experimentally by using a His6-MBP-mEYFP recombinant substrate containing the predicted target sequence. Our results highlight both potentials and limitations of the tested algorithms. The identification of candidate host substrates of 3CLpro may help better develop an understanding of the molecular mechanisms behind the replication and pathogenesis of SARS-CoV-2.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
host protein cleavage
cleavage site prediction
cleavage site identification
SSHHPS
NetCorona
COVID-19
SARS
SARS-CoV-2
protease
3CL protease
coronavirus
main protease
Megjelenés:International Journal Of Molecular Sciences. - 21 : 24 (2020), p. 1-19. -
További szerzők:Golda Mária (1986-) (molekuláris biológus) Kunkli Balázs Nagy Tibor (1988-) (vegyész) Tőzsér József (1959-) (molekuláris biológus, biokémikus, vegyész) Mótyán János András (1981-) (biokémikus, molekuláris biológus)
Pályázati támogatás:GINOP-2.3.3-15-2016-00021
GINOP
NKFIH-1150-6/2019
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1